<DOC>
	<DOCNO>NCT02623998</DOCNO>
	<brief_summary>The purpose study determine whether patient early type 2 diabetes , short-term intensive metabolic intervention comprise sitagliptin , metformin , basal insulin glargine lifestyle approach superior standard diabetes therapy achieve sustain diabetes remission .</brief_summary>
	<brief_title>Remission Evaluation Metabolic Intervention Type 2 Diabetes With Sitagliptin ( REMIT-Sita )</brief_title>
	<detailed_description>This multicentre , open-label , randomize control trial 100 patient recently-diagnosed T2DM . Participants randomize 2 treatment group : ( ) 12-week course treatment sitagliptin , metformin , insulin glargine lifestyle therapy , ( b ) standard diabetes therapy , follow total 64 week ( 1 year 3 month ) . In participant HbA1C &lt; 7.3 % 12 week visit , glucose-lowering medication discontinue participant encourage continue lifestyle modification regular glucose monitoring . Participants HbA1C ≥ 7.3 % visit meet criterion hyperglycemic relapse stop drug receive standard glycemic management inform current Canadian Diabetes Association clinical practice guideline</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1. men woman 3080 year age inclusive ; 2. type 2 diabetes mellitus diagnosed physician within 5 year prior patient enrollment ; 3. antidiabetic drug regimen ( either drug dose drug ) unchanged 8 week prior screen randomization ; 4 . HbA1C ≤ 9.5 % oral hypoglycemic agent HbA1C ≤ 8.0 % 1 oral agent halfmaximal dose 2 agent ; 5. body mass index ≥ 23 kg/m2 ; 6. negative pregnancy test agreement use reliable method birth control duration trial female childbearing potential ; 7. ability willingness perform selfmonitoring capillary blood glucose ( SMBG ) ; ability willingness selfinject insulin ; 8. provision inform consent . 1. current use insulin ; 2. history hypoglycemia unawareness ; history severe hypoglycemia require assistance within last 5 year ; 3. renal dysfunction evidence serum creatinine ( Cr ) ≥ 124 μmol/l ; 4. history lactic acidosis diabetic ketoacidosis ; 5. active liver disease elevate alanine transferase ( ALT ) level ≥ 2.5 time upper limit normal time enrollment ; 6. history pancreatitis ; 7. cardiovascular disease include : ) systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 105 mmHg ; b ) peripheral vascular disease ; c ) leave bundle branch block second third degree AV block ; ) tachyarrhythmias bradyarrhythmias uncontrolled ventricular rate ; e ) stenotic valvular heart disease ; f ) cardiomyopathy ; g ) history heart failure ; h ) history aortic dissection ; ) document history angina coronary artery disease ; j ) history stroke transient ischemic attack ; 8. history disease require continuous systemic glucocorticoid treatment ; 9. history major illness life expectancy &lt; 3 year ; 10. history injury condition significantly limit participant 's ability achieve moderate level physical activity ; 11. excessive alcohol consumption ( &gt; 14 alcoholic drink per week men &gt; 7 alcoholic drink per week woman ) ; 12. know hypersensitivity insulin glargine , metformin , DPP4 inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glargine</keyword>
	<keyword>Metformin</keyword>
	<keyword>Sitagliptin</keyword>
	<keyword>Diet</keyword>
	<keyword>Excercise</keyword>
	<keyword>Lifestyle</keyword>
</DOC>